Towards Healthcare
Non-Small Lung Carcinoma Market Size, Trends and Companies Analysis

Non-Small Lung Carcinoma Market Size Envisioned at USD 21.51 Billion by 2033

The report covers Non-Small Lung Carcinoma Market Trends and Analysis segmented in terms of types covering Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma and others. The report delves into treatment types, including Chemotherapy, Targeted Therapy and Immunotherapy. The distribution channels including Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy are accessed. The report offers the value (in USD Billion) for the above segments.

Non-Small Lung Carcinoma Market Size and Future Overview Analysis

The non-small lung carcinoma market was valued at US$ 8.27 billion in 2023 and is predicted to reach US$ 21.51 billion by the end of 2033, representing an impressive CAGR of 10.03% from 2024 to 2033. Clinical research, development of new treatment options, and prevalence of NSCLC is driving the growth of the market.

Non-Small Lung Carcinoma Market Size 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • By region, North America dominated the non-small lung carcinoma market in 2023, and it is expected to remain dominant during the forecast period.
  • By region, Asia Pacific is estimated to grow at the fastest CAGR during the forecast period of 2024-2033.
  • By type, the adenocarcinoma segment dominated the market in 2023.
  • By type, the squamous cell cancer segment is expected to grow at the fastest CAGR during the forecast period.
  • By treatment, the targeted therapy segment dominated the market in 2023.
  • By treatment, the immunotherapy segment is expected to grow significantly during the forecast period.
  • By distribution channel, the hospital pharmacy segment dominated the non-small lung carcinoma market in 2023.

Industry at a Glance

Non-small cell lung cancer (NSCLC) is the most common type. Around 85% of lung cancer cases are NSCLC. This illness is caused by cancer cells found in lung tissue. While NSCLS progresses more slowly than small-cell lung cancer, it often has spread to other parts of the body by the time it is detected. Timely diagnosis and treatment are of utmost importance. The non-small lung carcinoma market is growing due to the increasing prevalence of lung cancer. The major cause of lung cancer is smoking, and other factors that contribute to NSCLC are air pollution, industrial substances, radiation exposure and tuberculosis. Early detection and treatment of NSCLC are needed.

Laboratory tests, chest X-rays, CT scans, biopsy, sputum cytology, bronchoscopy, thoracoscopy and thoracentesis are some of the diagnoses and tests that need to be done, which drive the growth of the non-small lung carcinoma market. Furthermore, treatment, medications, hospital admission, continuous monitoring, and post-treatment recovery are involved after diagnosis. With time, the cases of NSCLC are increasing; hence, the need for all the tests, treatments, monitoring and other procedures will continue to increase.

Occurrence of NSCLC v/s SCLC

Top Companies of the Non-Small Lung Carcinoma Market

  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Sanofi, Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Boehringer Ingelheim

Pfizer Inc. Pipeline for NSCLC

Company Name Pfizer Inc.
Headquarters New York, U.S.

The clinical trial is in progress, and NSCLC is being studied. According to the Pfizer Pipeline Report published in May 2024,

  • Compound Name: sigvotatug vedotin (PF08046047)
  • Indication: 2L Non-Small Cell Lung Cancer (NSCLC) (SGNB6A-002) (Biologic)
  • Mechanism of Action: Integrin beta-6-directed antibody-drug conjugate
  • Phase of Development: Phase 3

AstraZeneca Pipeline for NSCLC

Company Name AstraZeneca
Headquarters Cambridge, United Kingdom

According to the pipeline report published by the company in February 2024, there are 19 projects in the pipeline that revolve around NSCLC, many of which will be submitted by 2025.

Compound Name List in the Pipeline

  • ceralasertib +Imfinzi LATIFY
  • datopotamab deruxtecan AVANZAR
  • datopotamab deruxtecan TROPION-Lung07
  • datopotamab deruxtecan TROPION-Lung08
  • Imfinzi +/- oleclumab+/- monalizumab PACIFIC-9
  • volrustomig eVOLVE-Lung02
  • Enhertu DESTINY-Lung04
  • Imfinzi + CRT PACIFIC-5 (China)
  • Imfinzi + domvanalimab (AB154) PACIFIC-8
  • Imfinzi post-SBRT PACIFIC-4
  • Tagrisso + Orpathys SAFFRON
  • Tagrisso ADAURA2

Smoking on a Large Scale is the Leading Cause of NSCLC, which Drives the Market's Growth

Smoking is the leading cause of various cancers such as lung, stomach, pancreas, esophagus, mouth, voice box, throat, leukemia, rectum, colon, cervix, and bladder. Among all the cases of cancer, smoking is responsible for 85%.  Smoking is the most common cause of NSCLC, and 95% of NSCLC cases can be prevented if restrictions on smoking are applied. Many governments have implemented various policies and regulations, like the prohibition of tobacco advertisements, to prevent smoking.

  • According to the World Health Organization, around 1.3 billion people use tobacco products, which leads to 8 million deaths of smokers and 1.3 million deaths of second-hand smokers every year.

The Expensive Nature of the Treatment Procedure Restricts the Growth of the Non-small Lung Carcinoma Market

There are numerous factors that contribute to the expensive nature of carcinoma treatment. Drug development, including clinical trials and research & development, is the major factor that makes the treatment expensive because it requires huge investment in terms of time and cost. The healthcare professionals involved in the treatment procedure are highly skilled, which is why they are highly compensated. This also contributes to the costs. The technology and infrastructure involved in cancer treatment are also advanced and expensive. It becomes difficult for people who belong to poor and middle-class families and also who live in developing or underdeveloped countries. According to the WHO, 80% of active smokers live in low- and middle-income countries, which suggests that these people will not be able to afford the treatment costs if they get diagnosed with NSCLC.

Minimally Invasive Surgery Can Help in Growing the Non-Small Lung Carcinoma Market

The field of surgery has seen significant transformation in the past 20 years due to minimally invasive surgery (MIS). Particularly for early-stage lung cancer, techniques like robotic-assisted thoracoscopic surgery (RATS) and video-assisted thoracoscopic surgery (VATS) have taken the lead in thoracic surgery and are now considered the new norm for most surgeries. Notwithstanding these advancements, hard evidence about the therapeutic results of these minimally invasive techniques in comparison to traditional open surgery is still lacking. The frequency of minimally invasive operations is expected to continue rising in the future as lung cancer screening programs lead to an increase in the early detection of lung cancer nodules. This is going to play a significant role in the growth of the non-small lung carcinoma market.

For instance,

  • In March 2024, Porter expanded its extensive range of cutting-edge medical treatments for lung problems to include robotic-assisted lung biopsies. This cutting-edge technology gives patients a less intrusive way to get accurate diagnostic information, which is a key milestone in the early identification and treatment of lung cancer.
  • In January 2024, with assistance from Shanghai medical personnel, Zhejiang Province surgeons performed the first minimally invasive lung cancer procedure on Saturday while under acupuncture anesthesia. Using the TCM-based treatment, a tubeless approach was adopted during the surgery to minimize stress and promote a faster recovery. The 67-year-old patient was permitted to walk back to her ward after the treatment.

Report Highlights

By Type

By type, the adenocarcinoma segment dominated the non-small lung carcinoma market in 2023. Adenocarcinoma is the most common kind of lung cancer, and the majority of lung cancers are non-small cell lung cancers (NSCLC). This kind of lung cancer represents around 40% of all lung cancer cases and 50% of non-small cell lung cancer cases. In many situations, lung adenocarcinoma can be detected in scars or regions with persistent inflammation, typically affecting the periphery of the lung. The biggest risk factor for adenocarcinoma and all other types of lung cancer is tobacco use. Other risk factors that can cause adenocarcinoma are chromium, genetics, arsenic, nickel, lung scarring, polycarbonate, pulmonary fibrosis and exposure to radiation.

By type, the squamous cell cancer segment is expected to grow at the fastest CAGR during the forecast period. The origins of squamous cell lung cancer are the thin, flat squamous cells that, when seen under a microscope, resemble fish scales. If the tumor grows very large, a chest X-ray or computed tomography (CT) scan may be used to identify a lung cavity. Biopsies, imaging examinations, and laboratory testing are a few of the methods used to diagnose lung cancer. Biomarkers are features of cancer that can be used to predict the disease's response to particular treatments. Nowadays, driver mutations discovered in the DNA of the illness and PD-L1 protein levels are used as biomarkers to inform treatment choices for squamous cell lung cancer.

By Treatment Type

By treatment, the targeted therapy segment dominated the non-small lung carcinoma market in 2023. Antagonists in targeted treatment specifically target the genes, proteins, or tumor microenvironment that promotes the growth and survival of cancer. Standard chemotherapy medications do not function in the same way as targeted treatments. They frequently have distinct adverse effects and occasionally function when chemotherapy medications don't. Currently, targeted medications are most frequently utilized, either alone or in combination with chemotherapy, to treat advanced lung malignancies. Targeted treatment is pushing the envelope to dramatically enhance patient outcomes and quality of life for advanced non-small cell lung cancer (NSCLC) patients without a confirmed driving mutation. There are several FDA-approved targeted medicines, and a large number of developing medications target these pathways. The rate at which scientific research is progressing is causing a fast change in the treatment of non-small cell lung cancer.

For instance,

  • In October 2023, the FDA approved Pfizer’s encorafenib+binimetinib for the treatment of BRAFV600E-mutant metastatic NSCLC. The BRAFTOVI+MEKTOVI is a targeted combination therapy that can be used for both previously treated and naïve BRAFV600E-mutant metastatic NSCLC.

By treatment, the immunotherapy segment is expected to grow significantly during the forecast period. One of the most recent treatments for metastatic non-small-cell lung cancer is immunotherapy. It is not the same as chemotherapy. Rather than targeting cancer cells while they divide, it makes use of your immune system to eradicate cancer and prevent it from spreading. Immunotherapy, which has been developed over many decades, has shown promise in producing long-lasting responses in a variety of cancer types. Over the past ten years, immunotherapy has shown to be a successful treatment strategy for non-small cell lung cancer. Patients and doctors may now customize therapy based on unique features for metastatic NSCLC because of the availability of many FDA-approved regimens.

By Distribution Channel

By distribution channel, the hospital pharmacy segment dominated the non-small lung carcinoma market in 2023. Hospital pharmacies are integral to cancer treatment for several reasons. Hospitals provide a range of specialized services, including surgery, chemotherapy, radiation therapy, and other crucial medical interventions. They have the necessary infrastructure, medical equipment, and trained staff to deliver complex cancer treatments. Additionally, hospitals often have specialized oncology departments staffed with oncologists and other cancer specialists who can provide comprehensive care. Pharmacies play a vital role by ensuring that patients have access to the required medications for their cancer treatment. They dispense prescription drugs, including chemotherapy drugs, supportive medications, and pain management medications. Pharmacists also provide crucial guidance on medication usage, potential side effects, and interactions with other drugs.

Regional Insights

By region, North America dominated the non-small lung carcinoma market in 2023 and is expected to remain dominant during the forecast period. North America is known for its advanced technology, developed healthcare infrastructure, government support and regulations, and continuous research and development. All these factors contribute to the growth of the market. The U.S. and Canada are the two major countries in the North American region that contribute to the growth.

Estimated New Cases and Deaths in the U.S., 2024
  Male Female Total
Estimated New Cases 116,310 118,270 234,580
Estimated Deaths 65,790 59,280 125,070


The U.S. has the dominant market share in the North American region, followed by Canada. The second most prevalent cancer in the U.S. for both men and women is lung cancer, including non-small cell lung cancer. About one in five cancer fatalities in the U.S. are due to lung cancer, making it the primary cause of cancer death overall. Lung cancer claims more lives annually than the combined totals of colon, breast and prostate cancer.

  • President Biden relaunched the 2016 Cancer Moonshot initiative under new White House leadership on February 2, 2022. Michael Regan, the administrator of the Environmental Protection Agency and the heads of over fifteen bureaus, departments, and agencies comprise the President's "Cancer Cabinet," which he assembled as part of this endeavor. The President's objective of "ending cancer as we know it" is furthered by the Cancer Cabinet's activities, which coordinate efforts throughout the federal government. The Cancer Cabinet set five priorities in June 2022: reducing the impact of cancers that can be prevented, understanding and addressing environmental exposure, closing the screening gap, bringing patients and communities access to state-of-the-art research, and providing support to patients and caregivers.

By region, Asia Pacific is estimated to grow at the fastest CAGR during the forecast period of 2024-2033. Asia Pacific has both developed and developing countries that contribute to the growth of the non-small lung carcinoma market. Countries like China, India, Japan, and South Korea contribute to the growth of the market.

Lung cancer is the primary cause of cancer-related fatalities globally and the top cause of mortality for Chinese citizens. In China, the prevalence of lung cancer has been steadily rising during the previous 30 years. According to estimates, China presently sees between 0.8 and 1 million newly diagnosed instances of lung cancer each year, and for a while, this number is predicted to rise. In China, lung cancer is the primary cause of cancer-related deaths. Typically, when lung cancer is diagnosed, 65–70% of individuals have already progressed to an incurable stage. China is making efforts to tackle the prevalence of the NSCLC.

For instance,

  • A new medicine from China has shown unprecedented effectiveness in treating rare lung cancer cases. Sunvozertinib's phase 2 clinical trial demonstrates a 61% anti-tumor activity response, and the drug is intended to treat a particular kind of lung cancer.

In the case of India, the non-small lung carcinoma market is growing due to the increasing number of lung cancer cases and initiatives taken by India to tackle the issue. With 8–9 lakh cases each year, cancer is a serious public health concern. The nation has an estimated 25 lakh cases at any given time. Every year, cancer claims the lives of almost 4 lakh people. In the country, tobacco use has been connected to 40% of cancer cases. The Tertiary Treatment Cancer Centers (TCCC) initiative in India aims to develop or improve 20 State Cancer Institutes (SCI) and 50 TCCCs to provide comprehensive cancer treatment nationwide. The scheme permits a "one-time grant" of Rs. 120 crores for each SCI and Rs. 45 crores per TCCC, which may be utilized for equipment purchases and building development.

Recent Developments in the Non-Small Lung Carcinoma Market

  • In June 2024, together, Immutep and MSD are starting a Phase III study to assess the efficacy of Immutep's immunotherapy in combination with chemotherapy and MSD's KEYTRUDA for the treatment of non-small cell lung cancer (NSCLC). Approximately 750 patients are expected to participate in the research, which has the potential to change the standard of treatment for NSCLC patients at all PD-L1 expression levels.
  • In October 2023, FirstLook Lung's first commercial launch was announced today by DELFI Diagnostics, Inc., a provider of easily accessible blood-based tests that offer a novel approach to improving cancer diagnosis. FirstLook is a blood test with a 99.7% negative predictive value (NPV) that determines the probability of detecting lung cancer with low-dose CT (LDCT) in a simple, accurate, and tailored manner.

Segments Covered in Non-Small Lung Carcinoma Market Report

By Type

  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma
  • Others

By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.


Surgery, radiation therapy, chemoradiation therapy, combination therapy, targeted therapy, immunotherapy, systemic therapy, chemotherapy, adjuvant therapy.

Coughing that gets worse with time, coughing up blood, loss of appetite, fatigue, weight loss, wheezing, chest pain, trouble swallowing, face swelling, hoarseness and trouble breathing.

Technological advancements and R&D, including personalized cancer vaccines, immunotherapy, CRISPR technology, and microorganisms that live in the body for treatment, will improve cancer treatment.

World Health Organization, Government of Canada, Centers for Disease Control and Prevention, National Cancer Institute, FDA, American Lung Association, and American Cancer Society.